UK pharma major GSK (LSE: GSK) today announced that, in connection with the mRNA patent settlement reached between CureVac ...

The coming week sees the pace of corporate results reporting ease slightly, but still includes some big names, including insuers Aviva and Beazley; ...

Tan’s venture capital firm, based in San Francisco, has made significant investments in Chinese tech companies, including Semiconductor Manufacturing International Corp (SMIC), China's largest chip ...

US healthcare stocks struggle in 2025 due to government policies, sparking interest from bargain hunters as valuations reach ...

Key Points Dynavax Technologies (NASDAQ:DVAX) exceeded analyst expectations in Q2 2025, reporting GAAP revenue of $95.4 million and GAAP diluted EPS of $0.14. HEPLISAV-B, Dynavax's two-dose adult ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

(NYSE: KVUE) today announced financial results for the second quarter ended June 29, 2025. "Kenvue has a strong portfolio of ...

AnaptysBio develops innovative antibody therapies for autoimmune and inflammatory diseases. Its business revolves around discovering and advancing engineered antibodies, with a current pipeline that ...

Announces positive data for rosnilimab, a pathogenic T cell depleter, through Week 38 from Phase 2b rheumatoid arthritis trialEnrollment completed for rosnilimab Phase 2 ulcerative colitis trial; ...

Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) fell 29.8% in the afternoon session after the company ...